Kim Choon-Mee, Park Ra-Young, Choi Mi-Hwa, Sun Hui-Yu, Shin Sung-Heui
Research Center for Resistant Cells, Chosun University Medical School, Gwangju 501-759, Republic of Korea.
J Infect Dis. 2007 Jan 1;195(1):90-8. doi: 10.1086/509822. Epub 2006 Nov 22.
We determined the ferrophilic characteristics of Vibrio vulnificus to evaluate the potential usefulness of iron chelation therapy for the prevention of V. vulnificus infection. Readily available non-transferrin-bound iron (NTBI) is required for the initiation of V. vulnificus growth under in vitro iron-limited conditions and human ex vivo conditions. NTBI aided efficient transferrin-bound iron (TBI) use by V. vulnificus, and the vulnibactin-mediated iron-uptake system was expressed after bacterial growth had been started by NTBI. V. vulnificus required higher NTBI levels for the initiation of growth, produced siderophores at lower levels, and used TBI less efficiently than other bacteria. In addition, the growth of V. vulnificus was inhibited by deferiprone, a clinically available iron chelator. These results show that V. vulnificus is a ferrophilic bacterium that requires higher NTBI levels than other pathogens and that iron chelation therapy might be an effective means of preventing the in vivo growth of V. vulnificus in susceptible patients.
我们测定了创伤弧菌的嗜铁特性，以评估铁螯合疗法在预防创伤弧菌感染方面的潜在效用。在体外铁限制条件和人体离体条件下，创伤弧菌的生长起始需要易于获取的非转铁蛋白结合铁（NTBI）。NTBI有助于创伤弧菌有效利用转铁蛋白结合铁（TBI），并且在NTBI启动细菌生长后，创伤弧菌会表达vulnibactin介导的铁摄取系统。与其他细菌相比，创伤弧菌起始生长需要更高水平的NTBI，产生的铁载体水平较低，且利用TBI的效率较低。此外，临床上可用的铁螯合剂去铁酮可抑制创伤弧菌的生长。这些结果表明，创伤弧菌是一种嗜铁细菌，与其他病原体相比需要更高水平的NTBI，并且铁螯合疗法可能是预防易感患者体内创伤弧菌生长的有效手段。
